Loading
A phase 1/2 trial of ivonescimab, datopotamab deruxtecan and osimertinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07535437 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 66 participants, started 2026-04-09 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab; Dato-DXd; Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: determine the maximum tolerated dose (MTD) (phase I); progression free survival (phase I); measure objective response rate (ORR) (phase II). Lung eligibility wording from the registry: "* Biopsy-proven metastatic non-small cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.